Business News • PR NewsWire • Novartis late-breaking data show Cosentyx® continues to deliver high skin clearance for majority of psoriasis patients at four years

Novartis late-breaking data show Cosentyx® continues to deliver high skin clearance for majority of psoriasis patients at four years

Novartis late-breaking data show Cosentyx® continues to deliver high skin clearance for majority of psoriasis patients at four years

EAST HANOVER, N.J., Oct. 1, 2016 /PRNewswire/ -- Novartis announced today new data showing Cosentyx® (secukinumab) delivers efficacy in patients with moderate to severe plaque psoriasis out to four years of treatment. These late-breaking data come from the extension study of the...

View More : http://www.prnewswire.com/news-releases/novartis-late-breaking-data-show-cosentyx-continues-to-deliver-high-skin-clearan...

Releted News by prnewswire

Regeneron and Sanofi Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in the New England Journal of Medicine

La Conferencia de Negocios Hispanos de Maryland ostenta un elenco estelar

Wells Fargo and Habitat for Humanity of Washington, D.C. Partner on Special Volunteer Events to Build Affordable Housing